Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

OBJECTIVES: Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. METHODS: We conducted a first‐in‐human phase I study using TLR7/8‐matured DCs transfected with RNA encoding the two AML‐associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichtenegger, Felix S, Schnorfeil, Frauke M, Rothe, Maurine, Deiser, Katrin, Altmann, Torben, Bücklein, Veit L, Köhnke, Thomas, Augsberger, Christian, Konstandin, Nikola P, Spiekermann, Karsten, Moosmann, Andreas, Boehm, Stephan, Boxberg, Melanie, Heemskerk, Mirjam HM, Goerlich, Dennis, Wittmann, Georg, Wagner, Beate, Hiddemann, Wolfgang, Schendel, Dolores J, Kvalheim, Gunnar, Bigalke, Iris, Subklewe, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053229/
https://www.ncbi.nlm.nih.gov/pubmed/32153780
http://dx.doi.org/10.1002/cti2.1117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053229/
https://www.ncbi.nlm.nih.gov/pubmed/32153780
http://dx.doi.org/10.1002/cti2.1117

Ejemplares similares